Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 89

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 89
---
 statements
are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in, or implied by, the forward-looking statements. Therefore, you should not rely
on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially
from those indicated in the forward-looking statements include, among others, the following: expectations regarding our Digital Asset
Treasury (“DAT”) strategy and ability to execute such strategy successfully, our limited commercial and DAT experience; limited
cash and history of losses; our ability to obtain adequate financing to fund our business operations or DAT strategy in the future; risks
relating to the treatment of crypto assets for U.S. and foreign tax purposes; regulatory developments related to crypto assets and crypto
asset markets; a determination that we are an investment company under the Investment Company Act of 1940, as amended (the “1940
Act”); any changes in the accounting treatment of cryptocurrency holdings; the risk that the price of the Company’s common stock
may be highly correlated to the price of the digital assets that it holds; our ability to achieve profitability; our ability to develop
a commercially feasible application based on our Thermo-Acoustic Enhanced Ultrasound (“TAEUS”) technology; market acceptance
of our technology; uncertainties associated with any future pandemic, including possible effects on our operations; results of our human
studies, which may be negative or inconclusive; our ability to find and maintain development partners; our reliance on collaborations
and strategic alliances and licensing arrangements; the amount and nature of competition in our industry; our ability to protect our intellectual
property; potential changes in the healthcare industry or third-party reimbursement practices; delays and changes in regulatory requirements,
policy and guidelines including potential delays in submitting required regulatory applications for Food and Drug Administration (“FDA”)
approval; our ability to obtain and maintain CE mark certification and secure required FDA and other governmental approvals for our TAEUS
applications; our ability to regain compliance with the listing standards of the Nasdaq Capital Market and maintain the listing of our